The Global Antibody Drug Conjugates Market Report is equipped with market data from 2014 to 2024. The report gives a market overview covering key drivers and risks factors. The report is bifurcated by top global manufactures mentioning sales, revenue and prices as applicable. It also evaluates the competitive scenario of the leading players. The report expands to cover regional market data along with type and application. The report forecasts sales and revenue from 2019 to 2024. The detailed sales channel is also covered in the study.
Antibody Drug Conjugates are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment.
Scope of the Report:
The preparation process of ADC’s involves great difficulty, inspite of these hurdles recently approved ADC’s have proved their worth for treatment of cancer. Thus, there is a strong pipeline of ADC’s that promises revolutionary changes in area of targeted therapy for cancer treatment. This market is driven by elements such as continuous improvement in the clinical data and technological advancements in the field of drug development shelling out innovative drugs into the market.
The worldwide market for Antibody Drug Conjugates is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019.
This report focuses on the Antibody Drug Conjugates in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- F. Hoffman-La Roche
- Novartis AG
- Takeda Pharmaceutical
- Pfizer
- Seattle Genetics
- Genentech
- Immunogen
- Progenics Pharmaceuticals
- Bayer Healthcare Pharmaceuticals
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Antibody Drug Conjugates product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Antibody Drug Conjugates, with price, sales, revenue and global market share of Antibody Drug Conjugates in 2017 and 2018.
Chapter 3, the Antibody Drug Conjugates competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Antibody Drug Conjugates breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Antibody Drug Conjugates market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Antibody Drug Conjugates sales channel, distributors, customers, research findings and conclusion, appendix and data source.